Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clopidogrel
Drug ID BADD_D00504
Description Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213] It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.[A180547] Clopidogrel was granted FDA approval on 17 November 1997.[L7213]
Indications and Usage For the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease.
Marketing Status Prescription; Discontinued
ATC Code B01AC04
DrugBank ID DB00758
KEGG ID D07729
MeSH ID D000077144
PubChem ID 60606
TTD Drug ID D0N0TZ
NDC Product Code 65977-0037; 0093-7314; 16729-218; 42543-713; 71335-1409; 42543-714; 65162-414; 68788-7645; 52605-083; 50090-5781; 50090-4918; 70518-0400; 61919-737; 52605-082; 63653-1171; 0024-1332; 63187-362; 70934-708; 61919-007; 33342-060; 68071-1578; 70771-1062; 68071-4138; 71335-0581; 63629-4728; 16729-219; 63653-1332; 0024-1171; 72578-012
Synonyms Clopidogrel | SC 25989C | SC 25990C | SR 25989 | Clopidogrel-Mepha | Clopidogrel Mepha | Clopidogrel Sandoz | Iscover | Clopidogrel Napadisilate | Clopidogrel Hydrochloride | PCR 4099 | PCR-4099 | Clopidogrel Besylate | Clopidogrel Besilate | Clopidogrel, (+)(S)-isomer | Plavix | Clopidogrel Bisulfate
Chemical Information
Molecular Formula C16H16ClNO2S
CAS Registry Number 113665-84-2
SMILES COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dementia19.20.02.001; 17.03.01.0010.000392%Not Available
Dementia Alzheimer's type19.20.03.001; 17.03.06.0010.000098%Not Available
Depressed level of consciousness17.02.04.0020.000307%
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.0140.000392%Not Available
Dermatitis bullous23.03.01.0020.000343%
Dermatitis exfoliative23.03.07.001; 10.01.01.0040.000245%
Dermatomyositis23.03.02.001; 15.05.01.002; 10.04.02.0010.000026%Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diabetes mellitus inadequate control05.06.01.004; 14.06.01.0040.000098%Not Available
Diarrhoea07.02.01.001--
Diarrhoea haemorrhagic24.07.02.004; 07.02.01.0020.000245%Not Available
Dilatation ventricular02.04.02.0260.000147%Not Available
Diplegia17.01.04.0150.000098%Not Available
Diplopia17.17.01.005; 06.02.06.0020.000687%Not Available
Disability26.01.01.003--Not Available
Discomfort08.01.08.0030.000392%Not Available
Disorientation19.13.01.002; 17.02.05.0150.000883%Not Available
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.000205%
Disturbance in attention19.21.02.002; 17.03.03.001--
Diverticulitis11.01.07.003; 07.10.02.001--Not Available
Diverticulum07.10.01.0010.000245%Not Available
Diverticulum intestinal07.10.01.0020.000294%Not Available
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.003--
Dizziness exertional24.06.02.018; 17.02.05.034; 02.01.02.0130.000147%Not Available
Drug abuse19.07.02.010--Not Available
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.000392%Not Available
Drug hypersensitivity10.01.01.001--Not Available
Drug interaction08.06.03.001--Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 36 Pages